A $127M investment in external 'in-process research and development' (IPR&D) through licensing and collaboration agreements indicates a strategic push to bolster the innovation pipeline.
Filing excerpt
Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and its non-GAAP financial results for the second quarter 2026 will include an acquired in-process research and development (“IPR&D”) charge of approximately $127 million on a pre-tax basis.
What this signalsFilings often name leadership changes, deals and spending plans.
sec-8kdataInvestmentGet every 8-K signal for Regeneron and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Regeneron this week?”
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/ea24d849-c233-4e67-a666-25c0fbf20a5f returns this record as JSON. POST /v1/companies/enrich returns every signal for regeneron.com.
{
"signal_id": "ea24d849-c233-4e67-a666-25c0fbf20a5f",
"signal_type": "sec-8k",
"signal_subtype": "dataInvestment",
"detected_at": "2026-07-07T07:08:46.042+00:00",
"company": {
"name": "Regeneron",
"domain": "regeneron.com"
},
"data": {
"detail": "A $127M investment in external 'in-process research and development' (IPR&D) through licensing and collaboration agreements indicates a strategic push to bolster the innovation pipeline. This spending creates opportunities for vendors of research data platforms, clinical trial management systems, and collaboration tools needed to integrate and exploit these new assets.",
"metrics": {
"timeframe": "current_quarter",
"dollar_context": "Acquired in-process research and development (IPR&D) charge from collaboration and licensing agreements",
"dollar_millions": 127
},
"summary": "Regeneron announces $127M charge for acquired R&D via new collaborations",
"excerpts": "Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and its non-GAAP financial results for the second quarter 2026 will include an acquired in-process research and development (“IPR&D”) charge of approximately $127 million on a pre-tax basis.",
"relevance": 0.8,
"sentiment": "neutral",
"confidence": "medium",
"source_url": "https://www.sec.gov/Archives/edgar/data/872589/000110465926080562/tm2619682d1_8k.htm",
"filing_date": "2026-07-06",
"filing_year": 2026,
"sales_relevance": "Target for data vendors",
"signal_category": "technology"
}
}
curl https://signals.autobound.ai/v1/signals/ea24d849-c233-4e67-a666-25c0fbf20a5f \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"regeneron.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.